An opportunity for quantitative serological assay development for protective neutralizing antibodies to allow patients to track the status of their neutralizing antibody titers following vaccination or infection and help contain the spread of emerging infectious diseases (e.g., SARS-CoV-2 (COVID)).
Contact us for more information regarding investment or collaboration opportunities.